<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189445</url>
  </required_header>
  <id_info>
    <org_study_id>TAS-120-202</org_study_id>
    <secondary_id>2019-004084-49</secondary_id>
    <nct_id>NCT04189445</nct_id>
  </id_info>
  <brief_title>Futibatinib in Patients With Specific FGFR Aberrations</brief_title>
  <official_title>A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients&#xD;
      with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts:&#xD;
      patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4&#xD;
      rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]);&#xD;
      patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2&#xD;
      amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study TAS-120-202 is an open-label, multinational, 3-arm Phase 2 study evaluating the&#xD;
      efficacy, safety, tolerability, PK, and pharmacodynamics of futibatinib in patients with FGFR&#xD;
      aberrations. Eligible patients will be assigned to 1 of 3 treatment cohorts based on&#xD;
      diagnosis and FGFR gene aberration status.&#xD;
&#xD;
      Patients will receive futibatinib at an oral dose of 20 mg once a day on a continuous 28-day&#xD;
      cycle.&#xD;
&#xD;
      The study will enroll approximately:&#xD;
&#xD;
        -  Cohort A: 60 patients with locally advanced, advanced, or metastatic solid tumor&#xD;
           harboring FGFR rearrangements other than primary brain tumor or iCCA;&#xD;
&#xD;
        -  Cohort B: 35 patients with locally-advanced, advanced, or metastatic gastric cancer or&#xD;
           gastro-esophageal junction (GEJ) with FGFR2 amplification;&#xD;
&#xD;
        -  Cohort C: 20 patients with myeloid or lymphoid neoplasms (MLN) with FGFR1 rearrangements&#xD;
&#xD;
      Treatment in all cohorts will continue until disease progression, unacceptable toxicity, or&#xD;
      any other of the criteria for treatment discontinuation is met. For patients who discontinue&#xD;
      treatment for reasons other than disease progression, tumor assessments should be continued&#xD;
      until radiologic disease progression is documented or until initiation of subsequent new&#xD;
      anticancer therapy (whichever occurs first).&#xD;
&#xD;
      Patients will be followed for survival every 12 weeks (Â±2 weeks) until survival events&#xD;
      (deaths) have been reported for 75% of enrolled patients or the study is terminated early by&#xD;
      the Sponsor.&#xD;
&#xD;
      Additional cohorts may be added in the future in case of new emerging efficacy data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study consists of independent 3 cohorts (Cohorts A, B and C) and there is no difference in the treatment regimen between the cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in Cohorts A and B</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>ORR, defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1), based on independent central review of radiological images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (CR) rate in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>CR rate, defined as the proportion of patients who achieved a CR (per response criteria for MLN) based on investigators' assessment of imaging, peripheral blood, and bone marrow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR based on investigator assessment ORR in Cohorts A and B</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>ORR, defined as the proportion of patients experiencing a best overall response of partial response (PR) or complete response (CR) (per RECIST 1.1), based on investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Cohorts A, B and C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>DOR, defined as the time from the first documentation of response (CR or PR in Cohorts A and B; CR, PR, or CRi in Cohort C) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression- free survival (PFS) in Cohorts A, B and C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>PFS, defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Cohorts A, B and C</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>OS, defined as the time from the date of first dose to the death date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) in Cohort A and B</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>DCR, defined as the proportion of patients experiencing a best overall response of stable response (SD), PR, or complete response (CR) (per RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR+CRi rate in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>CR+CRi rate, defined as the proportion of patients who achieved a CR or CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Duration of CR, defined as the time from the first documentation of CR to the first documentation of recurrence or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR+CRi in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Duration of CR+CRi, defined as the time from the first documentation of CR or CRi to the first documentation of disease relapse or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete cytogenetic response (CCyR) rate in Cohort C.</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>CCyR rate, defined as the proportion of patients who achieved a CCyR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial cytogenetic response (PCyR) rate in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>PCyR rate, defined as the proportion of patients who achieved a PCyR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS) in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>RFS, defined as the time from first documentation of CR to the date of death (any cause) or disease relapse or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) in Cohort C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>EFS, defined as the time from first dose of study therapy to treatment failure, disease relapse after CR, or patient death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability in Cohorts A, B and C</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Safety based on reported AEs will be graded according to the National Cancer Institute- Common Terminology Criteria for Adverse events (NCI-CTCAE), Version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Advanced or Metastatic Solid Tumor</condition>
  <condition>Advanced or Metastatic Gastric or Gastroesophageal Cancer</condition>
  <condition>Myeloid or Lymphoid Neoplasms (MLN)</condition>
  <arm_group>
    <arm_group_label>Futibatinib (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid tumors harboring FGFR1-4 rearrangements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Futibatinib (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Futibatinib (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myeloid or lymphoid neoplasm harboring FGFR1 rearrangement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Futibatinib</intervention_name>
    <description>Futibatinib tablets will be dosed orally every day on a continuous 28-day cycle</description>
    <arm_group_label>Futibatinib (Cohort A)</arm_group_label>
    <arm_group_label>Futibatinib (Cohort B)</arm_group_label>
    <arm_group_label>Futibatinib (Cohort C)</arm_group_label>
    <other_name>TAS-120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          2. Known FGFR aberration status and tumor type that meet all of the criteria for 1 of the&#xD;
             following cohorts:&#xD;
&#xD;
             a. Cohort A&#xD;
&#xD;
             i. Histologically-confirmed, locally-advanced, advanced, or metastatic solid tumors&#xD;
             harboring a FGFR1-4&#xD;
&#xD;
        ii. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version&#xD;
        1.1&#xD;
&#xD;
        iii. Had disease progression/recurrence after standard treatment for their cancer&#xD;
&#xD;
        b. Cohort B&#xD;
&#xD;
        i. Histologically-confirmed, locally-advanced, advanced, or metastatic gastric or&#xD;
        gastroesophageal junction cancer harboring a FGFR2 amplification.&#xD;
&#xD;
        ii. Measurable disease per RECIST 1.1&#xD;
&#xD;
        iii. Received at least 2 prior systemic regimens for advanced/metastatic disease&#xD;
&#xD;
        iv. Experienced disease progression/recurrence during or after the most recent prior&#xD;
        systemic treatment for advanced/metastatic gastric cancer or GEJ cancer&#xD;
&#xD;
        c. Cohort C&#xD;
&#xD;
        i. Confirmed myeloid or lymphoid neoplasms as defined by WHO criteria with a FGFR1&#xD;
        rearrangement&#xD;
&#xD;
        ii. Not a candidate for hematological stem cell transplant (HSCT) or relapsed after HSCT&#xD;
        and donor lymphocyte infusion, and progressed and not a candidate for other therapies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History and/or current evidence of any of the following disorders:&#xD;
&#xD;
               1. Non-tumor related alteration of the calcium-phosphorus homeostasis that is&#xD;
                  considered clinically significant in the opinion of the Investigator&#xD;
&#xD;
               2. Ectopic mineralization/calcification including, but not limited to, soft tissue,&#xD;
                  kidneys, intestine, or myocardia and lung, considered clinically significant in&#xD;
                  the opinion of the Investigator&#xD;
&#xD;
               3. Retinal or corneal disorder confirmed by retinal/corneal examination and&#xD;
                  considered clinically significant in the opinion of the Investigator.&#xD;
&#xD;
          2. Prior treatment with an FGFR inhibitor&#xD;
&#xD;
          3. Brain metastases that are untreated or clinically or radiologically unstable (that is,&#xD;
             have been stable for &lt;1 month)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Osamu Takahashi, MD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234-2165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madappa Kundranda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Rosen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University - Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiwu He</last_name>
      <phone>202-444-8642</phone>
      <email>aiwu.r.he@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Nanda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Peters</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Woodhaven</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maen Abdelrahim, Prof</last_name>
      <phone>786-803-2333</phone>
      <email>mabdelrahim@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaffer Ajani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Aftimos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma Saada-Bouzid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Barthelemy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges FranÃ§ois Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>CÃ´te-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Ghiringhelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint-Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Paris</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques Kiladjian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Cassier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite cedex</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit You</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Hollebecque</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hong Kong United Oncology Centre</name>
      <address>
        <city>Kowloon</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Chung LI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gleneagles Hospital Hong Kong</name>
      <address>
        <city>Wong Chuk Hang</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Forli - Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Luca Frassineti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore Don Calabria</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Gori</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Melisi, Davide</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IEO Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Curigliano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Trento)</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Maria Vannucchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi-Ken</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba-Ken</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHO Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime-Ken</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka-Fu</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo-To</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Wook Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Hee Ryu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do-Youn Oh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Young Rha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frans Opdam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31107041906</phone>
      <email>m.lolkema@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo AntÃ³nio dos Capuchos</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Da Luz</last_name>
      <email>ricardo.luz@chlc.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FundaÃ§Ã£o Champalimaud</name>
      <address>
        <city>Lisboa</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuno Couto</last_name>
      <phone>+351210480200</phone>
      <email>nuno.couto@fundacaochampalimaud.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto, E.P.E - Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+351917258865</phone>
      <email>nuno.couto@fundacaochampalimaud.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Cancer Institute</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joline Lim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Ponz Sarvise</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda Cabanas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Carrato Mena</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cubillo Gracian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vicente Baz</last_name>
      <email>dvicentebaz@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia IVO</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Guerrero Zotano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Cervantes Ruiperez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montesinos Fernandez</last_name>
      <email>montesinos_pau@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska universitetssjukhuset - Solna</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umut Disel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem Maslak Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Namik Kemal University</name>
      <address>
        <city>TekirdaÄ</city>
        <zip>59100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burhan Turgut</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik-Tobias Arkenau</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Futibatinib</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastro-esophageal junction cancer</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Myeloid neoplasm</keyword>
  <keyword>Lymphoid neoplasm</keyword>
  <keyword>FGFR</keyword>
  <keyword>Amplification</keyword>
  <keyword>Rearrangement</keyword>
  <keyword>TAS-120</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Futibatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

